BioNexus Gene Lab Corp. (BGLC)
Automate Your Wheel Strategy on BGLC
With Tiblio's Option Bot, you can configure your own wheel strategy including BGLC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BGLC
- Rev/Share 5.157
- Book/Share 4.3253
- PB 1.3456
- Debt/Equity 0.0257
- CurrentRatio 4.1929
- ROIC -0.263
- MktCap 10456212.0
- FreeCF/Share -1.7915
- PFCF -3.2484
- PE -4.9375
- Debt/Assets 0.0211
- DivYield 0
- ROE -0.2419
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
Read More
BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory
Published: April 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission.
Read More
BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC's Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation.
Read More
BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper
Published: March 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
KUALA LUMPUR, Malaysia, March 06, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in technology and healthcare, is pleased to announce that its Board of Directors has formally approved the Company's new Ethereum-focused treasury strategy. This decision marks BGLC as the first Nasdaq-listed company to exclusively prioritize Ethereum (ETH) as a strategic treasury asset, and is in line with recent announcements of Ethereum being included in the US “Crypto Strategic Reserve”.
Read More
About BioNexus Gene Lab Corp. (BGLC)
- IPO Date 2021-01-08
- Website https://www.bionexusgenelab.com
- Industry Medical - Diagnostics & Research
- CEO Su-Leng Tan
- Employees 30